Arcus Biosciences, Inc. (RCUS)
29.21
-1.38
(-4.51%)
USD |
NYSE |
Aug 28, 16:00
29.18
-0.03
(-0.10%)
Pre-Market: 20:00
Arcus Biosciences Total Liabilities (Quarterly) : 460.00M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 460.00M |
| March 31, 2026 | 473.00M |
| December 31, 2025 | 933.00M |
| September 30, 2025 | 538.00M |
| June 30, 2025 | 526.00M |
| March 31, 2025 | 625.00M |
| December 31, 2024 | 665.00M |
| September 30, 2024 | 687.00M |
| June 30, 2024 | 551.00M |
| March 31, 2024 | 586.00M |
| December 31, 2023 | 633.00M |
| September 30, 2023 | 671.00M |
| June 30, 2023 | 654.00M |
| March 31, 2023 | 654.00M |
| December 31, 2022 | 688.00M |
| September 30, 2022 | 695.12M |
| June 30, 2022 | 729.39M |
| March 31, 2022 | 746.85M |
| Date | Value |
|---|---|
| December 31, 2021 | 750.45M |
| September 30, 2021 | 296.68M |
| June 30, 2021 | 294.22M |
| March 31, 2021 | 270.33M |
| December 31, 2020 | 269.99M |
| September 30, 2020 | 266.66M |
| June 30, 2020 | 52.68M |
| March 31, 2020 | 35.51M |
| December 31, 2019 | 39.27M |
| September 30, 2019 | 39.73M |
| June 30, 2019 | 42.33M |
| March 31, 2019 | 36.96M |
| December 31, 2018 | 39.98M |
| September 30, 2018 | 41.60M |
| June 30, 2018 | 39.29M |
| March 31, 2018 | 38.81M |
| December 31, 2017 | 36.62M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 2.434B |
| AVITA Medical, Inc. | 75.62M |
| Iovance Biotherapeutics, Inc. | 179.49M |
| Editas Medicine, Inc. | 132.08M |
| Recursion Pharmaceuticals, Inc. | 297.66M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 924.00M |
| Shareholders Equity (Quarterly) | 464.00M |
| Debt to Equity Ratio | 0.2457 |
| Current Ratio | 3.818 |
| Net Debt Paydown Yield | -0.28% |